Related Experiment Video

Updated: Aug 8, 2026

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries
08:58

En Face Detection of Nitric Oxide and Superoxide in Endothelial Layer of Intact Arteries

Published on: February 25, 2016

Strategies of protection from nitric oxide toxicity in islet inflammation

H Rothe1, H Kolb

  • 1Diabetes Research Institute at the Heinrich-Heine University of Düsseldorf, Germany.

Journal of Molecular Medicine (Berlin, Germany)
|February 4, 1999
PubMed

Insights

Nitric oxide contributes to type 1 diabetes by damaging islet cells. Suppressing poly-(ADP-ribose)-polymerase or inducing heat shock protein 70 protects these cells, offering new therapeutic avenues for diabetes.

Area of Science:

  • Immunology
  • Endocrinology
  • Molecular Biology

Background:

  • Nitric oxide (NO) is implicated in beta cell destruction during type I diabetes.
  • Inhibition of inducible nitric oxide synthase (iNOS) shows protective effects in vitro, but in vivo results are variable.
  • Alternative strategies to mitigate NO's cytotoxic effects on islet cells are needed.

Purpose of the Study:

  • To investigate methods for protecting islet cells from nitric oxide-induced damage.
  • To explore the role of NO in modulating immune responses, specifically Th1/Th2 reactivity, in diabetes progression.
  • To evaluate the therapeutic potential of targeting NO pathways and immune shifts in type 1 diabetes.

Main Methods:

  • Assessing islet cell survival upon exposure to nitric oxide under conditions of suppressed poly-(ADP-ribose)-polymerase (PARP) or induced heat shock protein 70 (HSP70).
  • Analyzing the impact of NO on Th1/Th2 immune responses, including the induction of interleukin-12 (IL-12) and its antagonist IL-12(p40)2.
  • Administering an IL-12 antagonist to prediabetic animals to observe effects on insulitis and iNOS expression.

Main Results:

  • Suppression of PARP or induction of HSP70 significantly enhanced islet cell survival when exposed to nitric oxide.
  • Nitric oxide modulates immune reactions by influencing Th1/Th2 balance, potentially via IL-12(p40)2 induction.
  • Administration of an IL-12 antagonist reduced islet inflammation and the upregulation of iNOS in prediabetic models.

Conclusions:

  • Targeting intracellular pathways like PARP suppression or HSP70 induction offers a novel approach to protect islet cells from NO toxicity.
  • Modulating the immune response, particularly by inhibiting IL-12, can ameliorate insulitis and decrease iNOS activity in type 1 diabetes.
  • These findings suggest potential therapeutic strategies for type 1 diabetes by simultaneously protecting beta cells and regulating immune-mediated inflammation.

More Related Videos

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice06:41

Minimizing Post-Infusion Portal Vein Bleeding during Intrahepatic Islet Transplantation in Mice

Published on: May 10, 2021

Isolated Pancreatic Islet Treatment and Apoptosis Measurement09:36

Isolated Pancreatic Islet Treatment and Apoptosis Measurement

Published on: May 2, 2025

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...